Deals this week: Aethlon Medical, Accuray, Amoy Diagnostics


Aethlon Medical Inc plans to issue shares of its common stock in a public offering to raise up to $13.28m.

The American company plans to use the funds to progress the development of its products as well as towards working capital and general corporate purposes.

US-based radiation oncology company Accuray Inc has announced the private placement of senior unsecured notes to raise $32m.

Due 15 July 2022, the notes carry an interest rate of 3.75% a year.

Accuray plans to use the funds to repurchase $28m of existing notes.

"Amoy plans to use the funds from the IPO towards new product investment, marketing, and R&D expansion."

Chinese molecular diagnostics company Amoy Diagnostics Co Ltd has announced the completion of an initial public offering (IPO) of 20 million shares priced at CNY13.86 ($2.06) each to raise CNY277m ($41.21m).

Amoy plans to use the funds from the IPO towards new product investment, marketing, and R&D expansion.

Invitae Corp plans to issue eight million preferred shares, priced at $8.5 a share, in a private placement to raise $73.5m.

The US-based genetic information company plans to use the proceeds to expand its business.